Ignite Creation Date:
2025-12-24 @ 9:19 PM
Ignite Modification Date:
2026-02-27 @ 10:33 AM
Study NCT ID:
NCT04768504
Status:
TERMINATED
Last Update Posted:
2024-11-25
First Post:
2021-02-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C479163', 'term': 'tofacitinib'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 2}}, 'statusModule': {'whyStopped': 'sponsor decision, due to low recruitment rate', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2022-03-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-11', 'completionDateStruct': {'date': '2024-01-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-20', 'studyFirstSubmitDate': '2021-02-20', 'studyFirstSubmitQcDate': '2021-02-20', 'lastUpdatePostDateStruct': {'date': '2024-11-25', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-02-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-01-17', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Clinical Remission of Diarrhea', 'timeFrame': '8 weeks from first dose', 'description': 'Resolution of diarrhea to grade 1 or less per Common Terminology Criteria for Adverse Events'}], 'secondaryOutcomes': [{'measure': 'Safety of tofacitinib', 'timeFrame': 'from first dose to 30 days post last dose', 'description': 'Defined as the occurrence of Grade 3 or higher adverse events'}, {'measure': 'Endoscopic remission', 'timeFrame': 'At 8 weeks', 'description': 'per Mayo score of less or equal than 2'}, {'measure': 'Time to clinical remission', 'timeFrame': 'from baseline to 8 weeks post first dose', 'description': 'time in days to resolution of diarrhea to grade 1 or less'}, {'measure': 'Tumor response status', 'timeFrame': '8 weeks from first dose', 'description': 'number of patient with PD by RECIST/iRECIST criteria'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Immune-related adverse events', 'Immune-related colitis'], 'conditions': ['Immune-Mediated Colitis']}, 'referencesModule': {'references': [{'pmid': '32521140', 'type': 'BACKGROUND', 'citation': 'Esfahani K, Hudson M, Batist G. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. N Engl J Med. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527. No abstract available.'}]}, 'descriptionModule': {'briefSummary': 'This is a single-arm pilot study evaluating the efficacy and safety of tofacitinib in cancer patients with immune-related colitis from immune checkpoint inhibitor (ICI) therapy.', 'detailedDescription': 'Primary objective and endpoint\n\n• Efficacy of tofacitinib in inducing clinical remission of immune related colitis, as measured by the proportion of patients who experience diarrhea resolution to grade ≤1 as per Common Terminology Criteria for Adverse Events \\[CTCAE\\] v5.0) without the requirement for additional immunosuppression (e.g., corticosteroids, biologics, or other immunosuppressors targeted for colitis) 8 weeks post-first dose of tofacitinib.\n\nSecondary objectives and endpoints:\n\n* Safety of tofacitinib in cancer patients with immune-related colitis, as defined by the occurrence of adverse events grade ≥3.\n* Efficacy of tofacitinib in cancer patients with immune colitis as defined by endoscopic remission of colitis (a total Mayo score of ≤2) at 8 weeks.\n* Efficacy of tofacitinib to induce a clinical remission of immune-related colitis as measured by the time, in days, necessary to achieve a diarrhea of grade ≤ 1 (as per CTCAE v 5.0).\n* Number of patients with tumor progression at 8 weeks per iRECIST and RECIST 1.1 criteria compared to baseline scans.\n\nExploratory objective\n\n• The study will collect blood samples from participants seeking to characterize the inflammatory landscape of ICI-mediated colitis and biomarkers predictive of response to tofacitinib.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. 18 years of age or older.\n2. Able to provide informed consent.\n3. Diagnosis of a solid tumor treated with an immune checkpoint inhibitor (ICI), with the exception of colorectal cancer.\n4. Exposure to an ICI (CTLA-4, PD-1, PDL-1) as part of a cancer treatment regimen within 6 months of the onset of colitis symptoms. The ICI may be used as a single agent, or in combination with other ICIs, or with chemotherapy.\n5. Current diagnosis of immune-related colitis characterized by grade ≥ 2 diarrhea as per CTCAE v5.0.\n6. Patients should have failed corticosteroids (at least 1mg/kg equivalent of prednisone for a minimum of 72 hours), and at least one dose of a biologic agent (i.e. either a TNFα inhibitor or an anti-integrin). Failure is defined as having ongoing grade ≥ 2 diarrhea per CTCAE v5.0.\n7. Adequate hematological function, defined by:\n\n 1. hemoglobin ≥ 90 g/L\n 2. absolute neutrophil count ≥ 1.0 x 109/L\n 3. lymphocyte count ≥ 0.5 x 109/L\n 4. platelets ≥ 75 x 109/L\n 5. PT, PTT, INR ≤ 1.5 x upper limit of normal (ULN).\n8. Adequate liver function, as assessed by the Child Pugh classification score (appendix 1). Patients with scores A and B are eligible for enrollment. Patients with severe hepatic impairment (Child Pugh C) are excluded from the study.\n9. Adequate renal function as defined by an estimated clearance ≥ 40 mL/min, calculated per the Cockroft-Gault formula (appendix 2).\n10. Women of childbearing potential (WOCBP) are eligible if they agree to use adequate contraception while on study. If in line with the patient\'s preference and usual lifestyle, complete abstinence from heterosexual intercourse is acceptable. WOCBP must otherwise agree to correctly and consistently use at least one "highly effective" in addition to one "effective" contraceptive methods:\n\nHighly effective means of contraception include the following:\n\n* Hormonal methods of contraception including combined oral contraceptives, vaginal ring, injectables, patch, implants, and intrauterine systems (IUSs).\n* Nonhormonal intrauterine devices (IUDs).\n* Tubal ligation\n* Vasectomy of the sole partner of a female subject\n* Male condoms with spermicide\n\nEffective means of contraception include the following:\n\n* Diaphragm with spermicide\n* Cervical cap with spermicide\n* Vaginal contraceptive sponge\n* Male condom without spermicide\n* Female condom (a male and female condom must not be used together)\n\nExclusion criteria:\n\n1. Diagnosis of a thromboembolic event (deep vein thrombosis, pulmonary embolism, embolic stroke, myocardial infarction, or peripheral arterial insufficiency) within 3 months of enrollment.\n2. Diagnosis of concomitant infectious colitis (e.g. C. difficile or other bacterial source), unless the patient has finished an appropriate length of treatment with antibiotics as indicated for each diagnosis at the time of enrollment.\n3. Any other grade ≥ 3 infection at the time of enrollment.\n4. Prior therapy with a JAK inhibitor within 3 months preceding enrollment.\n5. Use of strong inducers of CYP3A4 within 7 days of starting treatment with tofacitinib (see appendix 3).\n6. Known allergy or hypersensitivity to tofacitinib, its excipients or any of the drugs used in this study (valacyclovir, heparin, trimethoprim and sulfonamides).\n7. Active pregnancy or breastfeeding.\n8. Patients on intravenous biologic agents for other baseline autoimmune conditions.\n9. Patients having other concomitant uncontrolled irAEs at the time of enrollment which would require systemic corticosteroids or biologic immunomodulatory agents.'}, 'identificationModule': {'nctId': 'NCT04768504', 'briefTitle': 'Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study', 'organization': {'class': 'OTHER', 'fullName': 'Sir Mortimer B. Davis - Jewish General Hospital'}, 'officialTitle': 'An Open-label Study of Tofacitinib for the Treatment of Refractory Immune-related Colitis from ChecKpoint Inhibitor Therapy (TRICK)', 'orgStudyIdInfo': {'id': 'CR2108KE'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment Arm', 'description': 'Tofacitinib 10 mg PO BID for 30 days', 'interventionNames': ['Drug: Tofacitinib 10 mg']}], 'interventions': [{'name': 'Tofacitinib 10 mg', 'type': 'DRUG', 'description': 'Tofacitinib 10 mg PO BID for 30 days', 'armGroupLabels': ['Treatment Arm']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'H3T 1E2', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Sir Mortimer B Davis Jewish General Hospital - CIUSSS Centre-Ouest', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}], 'overallOfficials': [{'name': 'Khashayar Esfahani, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Jewish General Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Khashayar Esfahani', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Dr.', 'investigatorFullName': 'Khashayar Esfahani', 'investigatorAffiliation': 'Sir Mortimer B. Davis - Jewish General Hospital'}}}}